Sarsam @sclerodermaUM et al. Long term follow up of abatacept in SSc (ASSET). @RheumNow #ACR22 Abstr#1521
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial) - ACR Meeting Abstracts
